HC Wainwright Has Bearish Forecast for RIGL FY2026 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities researchers at HC Wainwright decreased their FY2026 earnings per share estimates for shares of Rigel Pharmaceuticals in a report released on Friday, November 6th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of $2.84 per share for the year, down from their previous forecast of $3.26. HC Wainwright currently has a “Buy” rating and a $85.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $2.98 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ FY2028 earnings at $5.21 EPS, FY2029 earnings at $5.96 EPS and FY2030 earnings at $7.03 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.27). The firm had revenue of $80.89 million for the quarter, compared to analysts’ expectations of $80.00 million. Rigel Pharmaceuticals had a net margin of 116.30% and a return on equity of 22.95%.

Several other brokerages also recently issued reports on RIGL. Piper Sandler reiterated a “neutral” rating and issued a $49.00 target price (up from $40.00) on shares of Rigel Pharmaceuticals in a research note on Monday, August 17th. Cantor Fitzgerald raised their price target on shares of Rigel Pharmaceuticals from $43.00 to $47.00 and gave the company a “neutral” rating in a research report on Friday. Zacks Research lowered shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Citigroup upped their price objective on Rigel Pharmaceuticals from $83.00 to $86.00 and gave the company a “buy” rating in a research report on Monday. Finally, Weiss Ratings upgraded Rigel Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $66.75.

Rigel Pharmaceuticals Stock Performance

Shares of Rigel Pharmaceuticals stock opened at $42.05 on Tuesday. The stock has a market capitalization of $777.92 million, a PE ratio of 2.71 and a beta of 1.28. Rigel Pharmaceuticals has a 52-week low of $24.95 and a 52-week high of $52.60. The company has a 50-day simple moving average of $47.70 and a two-hundred day simple moving average of $37.50.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Rigel Pharmaceuticals during the 2nd quarter valued at about $75,886,000. Assenagon Asset Management S.A. purchased a new stake in shares of Rigel Pharmaceuticals during the 3rd quarter valued at about $25,793,000. Bank of America Corp DE purchased a new stake in shares of Rigel Pharmaceuticals during the 2nd quarter valued at about $4,832,000. Globeflex Capital L P bought a new stake in shares of Rigel Pharmaceuticals in the second quarter worth approximately $4,408,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Rigel Pharmaceuticals in the second quarter worth approximately $4,233,000. Hedge funds and other institutional investors own 66.23% of the company’s stock.

Trending Headlines about Rigel Pharmaceuticals

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Citigroup raised its price target to $86 from $83 and maintained a Buy rating, signaling substantial upside in the analyst’s view. Citigroup recommendations
• Positive Sentiment: HC Wainwright also reiterated Buy with an $85 target. The favorable rating and target may support sentiment despite the firm’s lower forecasts.
• Negative Sentiment: HC Wainwright cut its EPS estimates for fiscal 2026, 2028, 2029 and 2030 to $2.84, $5.21, $5.96 and $7.03, respectively. The revisions reduce expectations for future earnings growth and may temper the benefit of the bullish price targets.
• Positive Sentiment: A separate analyst report raised Rigel’s price target to $47, another upward revision, although that target is below the $85–$86 objectives cited by other firms. Rigel Pharmaceuticals price target raised to $47

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) is a biotechnology company focused on developing and commercializing therapies for hematologic diseases, cancer and immune-related disorders. Founded in 1996 and headquartered in South San Francisco, California, the company uses small-molecule drug discovery and kinase biology to develop medicines that address unmet medical needs.

Rigel’s primary commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for treating thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.